|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
Austin, Texas, US
|
|
Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead product candidate, for the treatment of Arginase 1 Deficiency which has received both Rare Pediatric Disease and Breakthrough Therapy Designation. Aeglea has two programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline.
|
Aeglea BioTherapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Aeglea BioTherapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Aeglea BioTherapeutics customer service number in your country click here to find.
David G Lowe is the CEO of Aeglea BioTherapeutics. To contact David G Lowe email at [email protected]. Or you may call +1.5129422935
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.